Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Array BioPharma
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01828034
First received: April 5, 2013
Last updated: January 7, 2016
Last verified: January 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: April 2017
  Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)